Analysis of the combined effect of selinesol and bortezomib

Selinexor and bortezomib are two drugs commonly used to treat multiple myeloma (MM). They belong to different therapeutic classes, with selinesol being an oral XPO1 inhibitor and bortezomib being a proteasome inhibitor. The combined use of the two is gradually gaining clinical attention, especially for patients with multiple myeloma who are no longer sensitive to conventional treatments. The following is an analysis of the effects of the combined use of selinesol and bortezomib.

First of all, selinesol acts as a XPO1 inhibitor, which enhances the effect of anti-cancer proteins in tumor cells, such as p53 and other tumor suppressors by inhibiting nucleocytoplasmic export proteins (Exportin 1, XPO1). XPO1 is an important regulator of extracellular transport from the nucleus. Many anti-tumor factors and cell cycle regulatory factors are controlled by XPO1. By inhibiting XPO1, selinesol can lead to the accumulation of anti-tumor factors in tumor cells, thereby inhibiting the growth and division of tumor cells. Bortezomib, by inhibiting the function of the proteasome, causes the accumulation of unfolded or abnormal proteins in tumor cells, ultimately triggering cell apoptosis. Bortezomib and selinesol have different mechanisms of action, so combining these two drugs may produce synergistic antitumor effects.

Studies have shown that selinesol combined with bortezomib has positive clinical effects in the treatment of multiple myeloma. In some clinical trials, combination therapy has shown significant efficacy against treatment-resistant myeloma. Especially in relapsed or refractory patients, combination therapy can significantly improve the treatment response rate, and some patients even achieve complete remission. Combination therapy can not only target tumor cells through different mechanisms to avoid possible drug resistance caused by single therapy, but can also increase the intensity of attack on tumor cells, thus enhancing the therapeutic effect.

However, the combination of selinesol and bortezomib is not without challenges. First, the side effects of combination therapy may be increased. Selinisol itself may cause a range of side effects, such as fatigue, nausea, loss of appetite, and low platelets. Bortezomib often causes peripheral neuropathy, gastrointestinal reactions, and hematological toxicity. When these two drugs are used together, patients may face a greater burden of side effects. Therefore, during treatment, patients need to be closely monitored in order to detect side effects in time and handle them accordingly. Nonetheless, management of side effects has matured, and most patients tolerate the combination regimen.

Regarding future treatment prospects, the combination therapy of selinesol and bortezomib shows good potential in the treatment of multiple myeloma, especially in the face of multidrug resistance or relapsed patients. As more clinical trials and data accumulate, doctors will be able to better understand the best treatment options for combining the two drugs, including the dosage, duration of use, and strategies for managing side effects. The emergence of new drug combinations and treatment strategies has further improved the therapeutic effect of multiple myeloma and provided patients with more treatment options.

Overall, the combination of selinesol and bortezomib shows promise in the treatment of multiple myeloma, especially in those patients who are resistant or relapsed. Through the synergistic effect of the two drugs, the patient's treatment response rate is expected to be improved, but at the same time, close attention must be paid to the management of side effects. With the support of more research and data, this treatment option is expected to become one of the routine choices in clinical practice, bringing better survival and quality of life to patients with multiple myeloma.

Reference materials:https://www.selincro.com/